Scarica l'app Stockscreener
3.53
10.31%
0.33
Precedente Chiudi:
$3.20
Aprire:
$3.24
Volume 24 ore:
237.38K
Relative Volume:
1.16
Capitalizzazione di mercato:
$6.82M
Reddito:
$895.50K
Utile/perdita netta:
$-26.30M
Rapporto P/E:
-2.1524
EPS:
-1.64
Flusso di cassa netto:
$-23.84M
1 W Prestazione:
+9.63%
1M Prestazione:
-16.94%
6M Prestazione:
-65.93%
1 anno Prestazione:
-89.70%
Intervallo 1D:
$3.14
$3.58
Intervallo di 1 settimana:
$3.03
$3.58
Portata 52W:
$2.65
$40.40
Mainz Biomed N V Stock (MYNZ) Company Profile
Nome
Mainz Biomed N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MYNZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
3.53 | 6.82M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
424.24 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.14 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
437.44 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
106.28 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.28 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | Maxim Group | Buy |
| 2024-11-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | Iniziato | H.C. Wainwright | Buy |
Mainz Biomed N V Borsa (MYNZ) Ultime notizie
Long Term Trading Analysis for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Up 3.9% – What’s Next? - Defense World
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection - Markets Herald
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - ADVFN
(MYNZ) Investment Report - news.stocktradersdaily.com
Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World
Mainz Biomed (MYNZ) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Mainz Biomed begins pivotal colorectal cancer test study By Investing.com - Investing.com Canada
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - The Manila Times
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan
(MYNZ) Proactive Strategies - Stock Traders Daily
Mainz Biomed secures license for pancreatic cancer test By Investing.com - Investing.com Australia
Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq
Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer - Marketscreener.com
Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection - TipRanks
Mainz Biomed secures license for pancreatic cancer test - Investing.com India
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - The Manila Times
Mainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer Detection - Nasdaq
Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood ... - The Bakersfield Californian
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
(MYNZ) Trading Advice - Stock Traders Daily
Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire
Mainz Biomed Partners with labor team w ag to Launch ColoAlert® Colorectal Cancer Screening Test in Switzerland - Nasdaq
First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? - StockTitan
Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group - Defense World
Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq
How To Trade (MYNZ) - Stock Traders Daily
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire
Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq
Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan
A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News
The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed N V Azioni (MYNZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):